These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 29954099)

  • 41. Mesenchymal stem cells are attracted to latent HIV-1-infected cells and enable virus reactivation via a non-canonical PI3K-NFκB signaling pathway.
    Chandra PK; Gerlach SL; Wu C; Khurana N; Swientoniewski LT; Abdel-Mageed AB; Li J; Braun SE; Mondal D
    Sci Rep; 2018 Oct; 8(1):14702. PubMed ID: 30279437
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents.
    Passaes CPB; Bruel T; Decalf J; David A; Angin M; Monceaux V; Muller-Trutwin M; Noel N; Bourdic K; Lambotte O; Albert ML; Duffy D; Schwartz O; Sáez-Cirión A
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077644
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window.
    Sloane JL; Benner NL; Keenan KN; Zang X; Soliman MSA; Wu X; Dimapasoc M; Chun TW; Marsden MD; Zack JA; Wender PA
    Proc Natl Acad Sci U S A; 2020 May; 117(20):10688-10698. PubMed ID: 32371485
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency.
    Hashemi P; Barreto K; Bernhard W; Lomness A; Honson N; Pfeifer TA; Harrigan PR; Sadowski I
    EMBO Mol Med; 2018 Feb; 10(2):160-174. PubMed ID: 29246970
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostratin as a new therapeutic agent targeting HIV viral reservoirs.
    Hezareh M
    Drug News Perspect; 2005 Oct; 18(8):496-500. PubMed ID: 16391719
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection.
    Garcia-Vidal E; Badia R; Pujantell M; Castellví M; Felip E; Clotet B; Riveira-Muñoz E; Ballana E; Esté JA
    Antiviral Res; 2019 Aug; 168():18-27. PubMed ID: 31077767
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histone deacetylase inhibitors containing a benzamide functional group and a pyridyl cap are preferentially effective human immunodeficiency virus-1 latency-reversing agents in primary resting CD4+ T cells.
    Kobayashi Y; Gélinas C; Dougherty JP
    J Gen Virol; 2017 Apr; 98(4):799-809. PubMed ID: 28113052
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.
    Jones RB; Mueller S; O'Connor R; Rimpel K; Sloan DD; Karel D; Wong HC; Jeng EK; Thomas AS; Whitney JB; Lim SY; Kovacs C; Benko E; Karandish S; Huang SH; Buzon MJ; Lichterfeld M; Irrinki A; Murry JP; Tsai A; Yu H; Geleziunas R; Trocha A; Ostrowski MA; Irvine DJ; Walker BD
    PLoS Pathog; 2016 Apr; 12(4):e1005545. PubMed ID: 27082643
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The development of immune-modulating compounds to disrupt HIV latency.
    Remoli AL; Marsili G; Battistini A; Sgarbanti M
    Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART.
    Kulkosky J; Culnan DM; Roman J; Dornadula G; Schnell M; Boyd MR; Pomerantz RJ
    Blood; 2001 Nov; 98(10):3006-15. PubMed ID: 11698284
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus.
    Yang W; Sun Z; Hua C; Wang Q; Xu W; Deng Q; Pan Y; Lu L; Jiang S
    Microbes Infect; 2018; 20(9-10):626-634. PubMed ID: 29126877
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HIV latency reversing agents act through Tat post translational modifications.
    Khoury G; Mota TM; Li S; Tumpach C; Lee MY; Jacobson J; Harty L; Anderson JL; Lewin SR; Purcell DFJ
    Retrovirology; 2018 May; 15(1):36. PubMed ID: 29751762
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of celastrol as a novel HIV-1 latency reversal agent by an image-based screen.
    Liu H; Hu PW; Dubrulle J; Stossi F; Nikolai BC; Mancini MA; Rice AP
    PLoS One; 2021; 16(4):e0244771. PubMed ID: 33914760
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.
    Clutton G; Xu Y; Baldoni PL; Mollan KR; Kirchherr J; Newhard W; Cox K; Kuruc JD; Kashuba A; Barnard R; Archin N; Gay CL; Hudgens MG; Margolis DM; Goonetilleke N
    Sci Rep; 2016 Aug; 6():30749. PubMed ID: 27480951
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design.
    Ke R; Conway JM; Margolis DM; Perelson AS
    JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333308
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HIV "shock and kill" therapy: In need of revision.
    Abner E; Jordan A
    Antiviral Res; 2019 Jun; 166():19-34. PubMed ID: 30914265
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Which therapeutic strategy will achieve a cure for HIV-1?
    Cillo AR; Mellors JW
    Curr Opin Virol; 2016 Jun; 18():14-9. PubMed ID: 26985878
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.
    Marsden MD; Wu X; Navab SM; Loy BA; Schrier AJ; DeChristopher BA; Shimizu AJ; Hardman CT; Ho S; Ramirez CM; Wender PA; Zack JA
    Virology; 2018 Jul; 520():83-93. PubMed ID: 29800728
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication.
    Walker-Sperling VE; Pohlmeyer CW; Tarwater PM; Blankson JN
    EBioMedicine; 2016 Jun; 8():217-229. PubMed ID: 27428432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.